Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new renin inhibitor ACT-178882

Cardiovascular Therapeutics

Volumn 31, Issue 5, 2013, Pages 307-313

  Dingemanse, Jasper ^a   Nicolas, Laurent ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

ACT 178882; Age; Pharmacokinetics; Renin inhibitor; Sex

Indexed keywords

ACT 178882; PLACEBO; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL LABORATORY; COLD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FLATULENCE; FLUSHING; HEADACHE; HUMAN; INSOMNIA; INTESTINE MOTILITY; MALE; MULTIPLE DRUG DOSE; MYALGIA; NAUSEA; OPEN STUDY; PHYSICAL EXAMINATION; POLLAKISURIA; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SENSATION; SENSATION OF HEAVINESS; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; THROAT IRRITATION; TREATMENT DURATION; VITAL SIGN;

ACT-178882; AGE; PHARMACOKINETICS; RENIN INHIBITOR; SEX;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CYCLOPROPANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; RENIN; SEX FACTORS;

EID: 84883802127     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12022     Document Type: Article

References (25)

1. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50-e103.
2. Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2-therapy. Can J Cardiol 2010;26:249-258.
3. Morganti A, Lonati C. Aliskiren: The first direct renin inhibitor available for clinical use. J Nephrol 2011;24:541-549.
4. Shah NK, Choksi R, Epstein BJ. Less RAAS is more, or not. Expert Rev Cardiovasc Ther 2011;9:1363-1365.
5. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.
6. ® in high-risk patients with diabetes and renal impairment. Media Release. Available from: http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml [accessed 20 December 2011].
7. Corminboeuf O, Bezencon O, Remen L, et al. Piperidine-based renin inhibitors: Upper chain optimization. Bioorg Med Chem Lett 2010;20:6291-6296.
8. Dingemanse J, Nicolas L, Binkert C. Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. Fundam Clin Pharmacol DOI: 10.1111/j.1472-8206.2012.01060x. [Epub a head of print].
9. Hamilton M, Pickering GW, Roberts JA, Sowry GS. The aetiology of essential hypertension. I. The arterial pressure in the general population. Clin Sci (Lond) 1954;13:11-35.
10. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol 2004;57:6-14.
11. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67-76.
12. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499-523.
13. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42:107-121.
14. Boparai MK, Korc-Grodzicki B. Prescribing for older adults. Mt Sinai J Med 2011;78:613-626.
15. Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ 2008;336:606-609.
16. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 2010;17:571-584.
17. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol 2008;83:1-10.
18. Ali AK. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag 2011;7:337-344.
19. Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008;60:623-631.
20. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril. Hypertension 2002;39:E1-E8.
21. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 2003;43:211-227.
22. Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010;5:314-327.
23. Verdecchia P, Calvo C, Möckel V, Keeling L, Satlin A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007;16:381-391.
24. Jarugula V, Yeh CM, Howard D, Bush C, Keefe DL, Dole WP. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren. J Clin Pharmacol 2010;50:1358-1366.
25. Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: A pooled analysis of eight studies. J Hum Hypertens 2010;24:721-729.